Spatial Metabolomics in Kidney Disease: Unveiling Metabolic Landscapes for Precision Medicine

Abstract

Spatial metabolomics represents an innovative frontier in kidney disease research, offering unprecedented insights into the spatial distribution of metabolites within renal tissues. Leveraging advanced imaging mass spectrometry and computational analytics, this approach elucidates the metabolic heterogeneity associated with various kidney pathologies. This review synthesizes current evidence on the application of spatial metabolomics in kidney disease, encompassing epidemiology, pathophysiology, risk factors, clinical features, diagnostic frameworks, management strategies, recent advancements, and guideline-driven recommendations. The integration of spatial metabolomics holds promise for precision diagnostics, risk stratification, and the development of targeted therapeutics in nephrology.

Introduction

Kidney disease, encompassing acute kidney injury (AKI) and chronic kidney disease (CKD), affects millions globally and imposes significant morbidity and mortality. Traditional molecular profiling techniques, although informative, often overlook the spatial context of metabolic alterations within renal parenchyma. Spatial metabolomics bridges this gap by mapping metabolite distributions across tissue sections, thereby capturing metabolic microenvironments relevant to disease etiology, progression, and response to therapy. This review aims to provide a comprehensive analysis of the clinical and scientific significance of spatial metabolomics in kidney disease, integrating recent guideline-based evidence and translational implications.

Epidemiology / Disease Burden

CKD is a global health concern, affecting an estimated 10–15% of the adult population, with rising incidence due to aging, diabetes, and hypertension. AKI remains prevalent among hospitalized patients, often progressing to CKD or end-stage renal disease (ESRD). Despite advances in genomics and proteomics, metabolic dysregulation is a defining feature of kidney disease, frequently preceding overt clinical manifestations. The burden of kidney disease is compounded by limited early detection tools and suboptimal therapeutic responses, underscoring the need for novel diagnostic and prognostic approaches such as spatial metabolomics.

Pathophysiology

The pathogenesis of kidney disease involves complex interactions between cellular, metabolic, and microenvironmental factors. Renal tissues exhibit remarkable metabolic diversity, with distinct profiles in glomeruli, proximal tubules, and interstitium. Spatial metabolomics enables high-resolution mapping of metabolites such as amino acids, lipids, and energy substrates, revealing compartmentalized alterations in pathways like glycolysis, fatty acid oxidation, and mitochondrial function. This spatially resolved data provides mechanistic insights into fibrosis, inflammation, and maladaptive repair processes characteristic of CKD and AKI, facilitating the identification of metabolic signatures linked to disease progression and therapeutic resistance.

Risk Factors

Traditional risk factors for kidney disease include diabetes mellitus, hypertension, cardiovascular disease, obesity, and genetic predispositions. Spatial metabolomics has shed light on how these risk factors induce localized metabolic perturbations, such as increased oxidative stress in diabetic nephropathy or lipid accumulation in hypertensive nephrosclerosis. Environmental exposures, medication toxicity, and aging further modulate renal metabolic landscapes, contributing to heterogeneity in disease phenotypes and outcomes. Understanding risk factor-specific metabolomic patterns may enable earlier intervention and personalized risk assessment.

Clinical Features

Patients with kidney disease often present with non-specific symptoms—fatigue, edema, and changes in urine output—reflecting underlying metabolic disturbances. Spatial metabolomics facilitates the correlation between clinical features and region-specific metabolic alterations, such as impaired energy metabolism in ischemic segments or aberrant lipid profiles in sclerotic glomeruli. These insights support the development of spatially targeted biomarkers that may enhance early detection and monitoring of disease activity, particularly in subclinical or atypical cases.

Diagnosis

Current diagnostic modalities for kidney disease, including serum creatinine, estimated glomerular filtration rate (eGFR), and histopathology, lack sensitivity for early or focal metabolic changes. Spatial metabolomics, employing techniques like matrix-assisted laser desorption/ionization (MALDI) imaging and desorption electrospray ionization (DESI) mass spectrometry, allows direct visualization and quantification of metabolites within histological contexts. This enables the identification of metabolic gradients, lesions, and microdomains associated with pathological states. Integrating spatial metabolomic data with histopathology and molecular diagnostics enhances diagnostic accuracy and has the potential to redefine renal disease classification schemes.

Treatment & Management

Conventional management of kidney disease involves blood pressure control, glycemic management, renin-angiotensin-aldosterone system (RAAS) inhibition, and lifestyle modification. However, inter-patient and intra-renal heterogeneity often limit therapeutic efficacy. Spatial metabolomics supports precision medicine by uncovering patient-specific and region-specific metabolic vulnerabilities, potentially guiding the selection of targeted therapies. For example, spatial profiling may identify areas of persistent inflammation or metabolic exhaustion, informing the use of anti-fibrotic, anti-inflammatory, or metabolic modulators in personalized regimens.

Recent Advances / Emerging Therapies

Recent advances in spatial metabolomics include multiplexed imaging, single-cell resolution analyses, and artificial intelligence-driven interpretation of metabolomic datasets. These innovations have led to the discovery of novel biomarkers predictive of progression and therapeutic response, such as regionally elevated acylcarnitines or altered tryptophan metabolites in fibrotic kidneys. Emerging therapies, including SGLT2 inhibitors and metabolic reprogramming agents, are being evaluated in conjunction with spatial metabolomic profiling to assess their impact on renal metabolic architecture and optimize treatment strategies. Integration with spatial transcriptomics and proteomics promises a holistic view of kidney pathobiology and therapeutic targets.

Guideline Recommendations

While spatial metabolomics is not yet a standard of care, recent nephrology guidelines emphasize the importance of molecular and metabolic phenotyping for risk stratification and personalized therapy. The Kidney Disease: Improving Global Outcomes (KDIGO) consortium and related bodies advocate for research into spatial omics technologies and their clinical translation. Interdisciplinary collaboration among nephrologists, pathologists, and metabolomics experts is essential for the validation and implementation of spatial metabolomic assays in routine practice.

Conclusion

Spatial metabolomics is revolutionizing the understanding of kidney disease by revealing metabolic heterogeneity at unprecedented spatial resolution. This approach provides mechanistic insights, refines diagnostic paradigms, and paves the way for precision therapeutics. Continued research and clinical integration of spatial metabolomics will be pivotal in advancing nephrology, improving patient outcomes, and addressing the global burden of kidney disease.